Switzerland-based Quercis Pharma AG, a privately held biopharmaceutical company developing a set of advanced-phase clinical studies focused on the prevention of venous thromboembolism (VTE) in cancer patients, has signed an exclusive, global licensing agreement for two patents with the Beth Israel Deaconess Medical Center, an affiliate of Harvard Medical School, concentrating on modulation, risk reduction of thrombotic pathologies and thrombotic events in cancer patients, it was reported on Monday.
The patents are associated with the main pathways of thrombotic inhibitors, including P-selectin. They also relate to the transport of cancer cells in the blood and are likely to play a role in preventing and decreasing tumour metastases.
The terms of the transaction have not been revealed.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval